statement
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
D2T RA 2b상 Period 2 결과에서 600mg 지속 투약군이 통계적 유효성(p-value)을 달성하며 시장 기대를 뛰어넘는 서프라이즈 기록
Related claims
The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statement에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.하나증권 · statement10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다.하나증권 · statement